Literature DB >> 7740610

Hypericin as an inactivator of infectious viruses in blood components.

G Lavie1, Y Mazur, D Lavie, A M Prince, D Pascual, L Liebes, B Levin, D Meruelo.   

Abstract

BACKGROUND: Hypericin is a potent virucidal agent with activity against a broad range of enveloped viruses and retroviruses. The effective virucidal activity emanates from a combination of photodynamic and lipophilic properties. Hypericin binds cell membranes (and, by inference, virus membranes) and crosslinks virus capsid proteins. This action results in a loss of infectivity and an inability to retrieve the reverse transcriptase enzymatic activity from the virion. STUDY DESIGN AND METHODS: Since hypericin is devoid of adverse action in most blood components and blood analyses, it is investigated as an additive with potential to inactivate infective viruses in blood components intended for transfusion.
RESULTS: Complete inactivation of 10(6) tissue culture-infective doses of human immunodeficiency virus was obtained in whole blood and in diluted packed red cells after illumination with fluorescent light for 1 hour. Loss of viral infectivity to cultured CEM cells has been monitored by use of a detection assay for human immunodeficiency virus p55 in enzyme-linked immunosorbent assay and cytopathic assays. In physiologic media, hypericin interacts with albumin and lipoproteins, retaining the virucidal activity in bound form. The molecule is negatively charged and forms organic and inorganic monobasic salts (ion pairs) in physiologic pH. Various ion pairs differ in virucidal efficacy.
CONCLUSION: The apparent transfusibility of hypericin, taken together with the efficacy of the virucidal activity, the broad range of enveloped viruses affected, and the absence of adverse effects on stored red cells, may render hypericin useful for inactivation of infectious viruses in red cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7740610     DOI: 10.1046/j.1537-2995.1995.35595259149.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  13 in total

1.  Selected physical and chemical properties of commercial Hypericum perforatum extracts relevant for formulated product quality and performance.

Authors:  S H Kopleman; A NguyenPho; W S Zito; F X Muller; L L Augsburger
Journal:  AAPS PharmSci       Date:  2001

2.  Photodynamic efficacy of hypericin targeted by two delivery techniques to hepatocellular carcinoma cells.

Authors:  Maha Fadel; Kawser Kassab; Tareq Youssef
Journal:  Lasers Med Sci       Date:  2010-09       Impact factor: 3.161

3.  Virucidal agents in the eve of manorapid synergy.

Authors:  Angel S Galabov
Journal:  GMS Krankenhhyg Interdiszip       Date:  2007-09-13

4.  Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin.

Authors:  R Kerb; J Brockmöller; B Staffeldt; M Ploch; I Roots
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

5.  Hypericum in infection: Identification of anti-viral and anti-inflammatory constituents.

Authors:  Diane F Birt; Mark P Widrlechner; Kimberly Dp Hammer; Matthew L Hillwig; Jingqiang Wei; George A Kraus; Patricia A Murphy; Joeann McCoy; Eve S Wurtele; Jeffrey D Neighbors; David F Wiemer; Wendy J Maury; Jason P Price
Journal:  Pharm Biol       Date:  2009       Impact factor: 3.503

6.  Identification of light-independent inhibition of human immunodeficiency virus-1 infection through bioguided fractionation of Hypericum perforatum.

Authors:  Wendy Maury; Jason P Price; Melinda A Brindley; ChoonSeok Oh; Jeffrey D Neighbors; David F Wiemer; Nickolas Wills; Susan Carpenter; Cathy Hauck; Patricia Murphy; Mark P Widrlechner; Kathleen Delate; Ganesh Kumar; George A Kraus; Ludmila Rizshsky; Basil Nikolau
Journal:  Virol J       Date:  2009-07-13       Impact factor: 4.099

Review 7.  Recent Patents on Light-Based Anti-Infective Approaches.

Authors:  Imran Ahmed; Yanyan Fang; Min Lu; Quan Yan; Ahmed El-Hussein; Michael R Hamblin; Tianhong Dai
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2018

8.  Does St. John's Wort cause regression in gastrointestinal system adenocarcinomas?

Authors:  Serap Karaarslan; Suna Cokmert; Atilla Cokmez
Journal:  World J Gastrointest Oncol       Date:  2015-11-15

9.  Elucidation of the tumoritropic principle of hypericin.

Authors:  M Van de Putte; T Roskams; J R Vandenheede; P Agostinis; P A M de Witte
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

Review 10.  Necrosis avidity: a newly discovered feature of hypericin and its preclinical applications in necrosis imaging.

Authors:  Binghu Jiang; Jichen Wang; Yicheng Ni; Feng Chen
Journal:  Theranostics       Date:  2013-08-10       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.